{"id":5944,"date":"2025-02-06T09:27:12","date_gmt":"2025-02-06T15:27:12","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5944"},"modified":"2025-07-13T15:11:11","modified_gmt":"2025-07-13T20:11:11","slug":"nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/","title":{"rendered":"Nanoscope Therapeutics se presentar\u00e1 en la conferencia de inversores y directores ejecutivos de BIO"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<p>\u00a0<\/p>\n<p><span class=\"legendSpanClass\" style=\"font-size: 16px;\"><span class=\"xn-location\">DALLAS<\/span><\/span><span style=\"font-size: 16px;\">,\u00a0<\/span><span class=\"legendSpanClass\" style=\"font-size: 16px;\"><span class=\"xn-chron\">6 de febrero de 2025<\/span><\/span><span style=\"font-size: 16px;\">\u00a0 \u2014 <\/span><a style=\"font-size: 16px;\" href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a><span style=\"font-size: 16px;\">, una empresa de biotecnolog\u00eda comprometida con la restauraci\u00f3n de la visi\u00f3n en pacientes ciegos en entornos del mundo real mediante el desarrollo y la comercializaci\u00f3n de nuevas terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy que\u00a0<\/span><span class=\"xn-person\" style=\"font-size: 16px;\">Sulagna Bhattacharya<\/span><span style=\"font-size: 16px;\">, director ejecutivo y cofundador de Nanoscope Therapeutics, presentar\u00e1 en la Conferencia BIO para directores ejecutivos e inversores, que tendr\u00e1 lugar en\u00a0<\/span><span class=\"xn-chron\" style=\"font-size: 16px;\">10 y 11 de febrero de 2025<\/span><span style=\"font-size: 16px;\">, en\u00a0<\/span><span class=\"xn-location\" style=\"font-size: 16px;\">Nueva York, NY<\/span><span style=\"font-size: 16px;\">. Los detalles de la presentaci\u00f3n son los siguientes:<\/span><\/p>\n<\/div>\n<\/div>\n<div class=\"col-sm-4 col-xs-12 col-vcenter\">\n<div class=\"image logo logo-wrapper\" data-src=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-asset-type=\"photo\" data-asset-label=\"Logo\" data-download-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg\" data-tweet-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-pinterest-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-linkedin-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-facebook-share-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-twitter-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=twitter\" data-facebook-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=facebook\" data-pinterest-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-linkedin-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=linkedin\">\n<p>La Sra. Bhattacharya ofrecer\u00e1 una actualizaci\u00f3n sobre las actividades cl\u00ednicas y corporativas de Nanoscope el lunes 10 de febrero a las\u00a0<span class=\"xn-chron\">4:30 p. m., hora del este<\/span>\u00a0en la Sala Plymouth. Los directivos de Nanoscope estar\u00e1n disponibles para reuniones durante la conferencia. Los asistentes interesados en programar una reuni\u00f3n pueden hacerlo a trav\u00e9s del sistema BIO One-on-One Partnering:\u00a0<a href=\"https:\/\/bcic.bio.org\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.bio.org\/events\/bio-ceo-investor-digital-conference\/partnering<\/a>.<\/p>\n<p>\u201cCon nuestra pr\u00f3xima solicitud de licencia biol\u00f3gica (BLA) para MCO-010, Nanoscope est\u00e1 a punto de brindar una restauraci\u00f3n significativa de la visi\u00f3n a pacientes que sufren de retinosis pigmentaria\u201d, declar\u00f3 la Sra. Bhattacharya. \u201cAgradezco esta oportunidad para destacar ante los asistentes los beneficios y aplicaciones de la terapia con MCO-010, as\u00ed como para hablar sobre nuestros otros programas cl\u00ednicos en desarrollo para indicaciones con necesidades m\u00e9dicas no cubiertas importantes. Espero que este evento sea muy productivo\u201d.\u201d<\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n y que no dependen de los genes para los millones de pacientes que han perdido la visi\u00f3n a causa de enfermedades degenerativas de la retina, para las que actualmente no existe cura. Tras los resultados positivos de final de estudio del ensayo cl\u00ednico RESTORE de fase 2b, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la RP (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan de iniciar un\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>\u00a0en el primer trimestre de 2025. La empresa ha completado el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>\u00a0en el primer trimestre de 2025. MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los programas precl\u00ednicos incluyen un activo MCO-020 no viral administrado por l\u00e1ser listo para IND para GA, as\u00ed como un activo AAV para amaurosis cong\u00e9nita de Leber, en estudios que permiten IND.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DA11655&Transmission_Id=202502041605PR_NEWS_USPR_____DA11655&DateId=20250204\" alt=\"\" \/><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>\u00a0 DALLAS,\u00a0Feb. 6, 2025\u00a0 \u2014 Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced that\u00a0Sulagna Bhattacharya, Chief Executive Officer and Co-Founder of Nanoscope Therapeutics, will present at the BIO CEO &#038; Investor Conference, taking place\u00a0February [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5945,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5944","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present at the BIO CEO and Investor Conference - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at the BIO CEO and Investor Conference - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-06T15:27:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:11:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_LI_BIOCEO_V2_REV.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_LI_BIOCEO_V2_REV.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at the BIO CEO and Investor Conference\",\"datePublished\":\"2025-02-06T15:27:12+00:00\",\"dateModified\":\"2025-07-13T20:11:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/\"},\"wordCount\":341,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/NSCOPE_LI_BIOCEO_V2_REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/\",\"name\":\"Nanoscope Therapeutics to Present at the BIO CEO and Investor Conference - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/NSCOPE_LI_BIOCEO_V2_REV.jpg\",\"datePublished\":\"2025-02-06T15:27:12+00:00\",\"dateModified\":\"2025-07-13T20:11:11+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/NSCOPE_LI_BIOCEO_V2_REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/NSCOPE_LI_BIOCEO_V2_REV.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/02\\\/06\\\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at the BIO CEO and Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus productos en la Conferencia de Directores Ejecutivos e Inversores de BIO - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at the BIO CEO and Investor Conference - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-02-06T15:27:12+00:00","article_modified_time":"2025-07-13T20:11:11+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_LI_BIOCEO_V2_REV.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_LI_BIOCEO_V2_REV.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at the BIO CEO and Investor Conference","datePublished":"2025-02-06T15:27:12+00:00","dateModified":"2025-07-13T20:11:11+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/"},"wordCount":341,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_LI_BIOCEO_V2_REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/","url":"https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/","name":"Nanoscope Therapeutics presentar\u00e1 sus productos en la Conferencia de Directores Ejecutivos e Inversores de BIO - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_LI_BIOCEO_V2_REV.jpg","datePublished":"2025-02-06T15:27:12+00:00","dateModified":"2025-07-13T20:11:11+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_LI_BIOCEO_V2_REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/02\/NSCOPE_LI_BIOCEO_V2_REV.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/02\/06\/nanoscope-therapeutics-to-present-at-the-bio-ceo-and-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at the BIO CEO and Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5944"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5944\/revisions"}],"predecessor-version":[{"id":7228,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5944\/revisions\/7228"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5945"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}